Showing results (131-140 of 219) with videos related to
Sort By:
Pageof 22
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 8, 2024
Neurological, psychological, psychosocial complications of long-COVID and their managementSareesh Naduvil Narayanan, Sreeshma Padiyath, Krishnapriya Chandrababu, et al.Cancer Medicine|October 16, 2018
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitorsAlejandro Zulbaran-Rojas, Huei-Kan Lin, Qiuling Shi, et al.Leukemia|October 9, 2021
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequencesAnneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, et al.Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.Future Oncology (London, England)|July 21, 2023
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinibRyan Jacobs, Xiaoxiao Lu, Bruno Emond, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 StudyJohn C Byrd, Richard R Furman, Steven E Coutre, et al.The Lancet. Haematology|March 19, 2018
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trialMaro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Stefan Faderl, et al.Cancer|December 4, 2018
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformationRashmi Kanagal-Shamanna, Preetesh Jain, Keyur P Patel, et al.Pageof 22